home / stock / lgvn / lgvn news

LGVN News and Press, Longeveron Inc. From 11/10/23

Stock Information
Company Name: Longeveron Inc.
Stock Symbol: LGVN
Market: NASDAQ
Website: longeveron.com
Menu
LGVN LGVN Quote LGVN Short LGVN News LGVN Articles LGVN Message Board
Get LGVN Alerts

News, Short Squeeze, Breakout and More Instantly...
LGVN - Expected earnings - Longeveron Inc.

Longeveron Inc. (LGVN) is expected to report $-0.24 for Q3 2023
LGVN - Sex Hormones Could Influence Alzheimer's Development, Researchers Say

University of Western Ontario researchers have discovered that sex hormones may play a role in the development of Alzheimer’s disease. The neurodegenerative condition affects roughly 32 million people globally and is characterized by disruptive symptoms such as poor judgment, memory lo...

LGVN - InvestorNewsBreaks - Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Plans to Release Q3 2023 Financial Report, Host Corporate Update Call

Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, has announced plans to report its financial results for Q3 2023. The company will release the results on Nov. 10, 2023, before the market ope...

LGVN - Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023

MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that it will report its third quarter 2023 financial...
LGVN - Longeveron Inc. (NASDAQ: LGVN) Validates Safety and Therapeutic Potential of its Lomecel-B(TM) Lead Investigational Product in its CLEAR MIND Phase 2a Clinical Trial

Longeveron, a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, reported positive top-line results from its CLEAR MIND Phase 2a human clinical trial The study, which explored Lomecel-B(TM)’s effects on mild Alzheimer...

LGVN - InvestorNewsBreaks - Longeveron Inc. (NASDAQ: LGVN; LGVNR) Top-Line Results from Phase 2a Trial Spotlighted in Latest NNA Release

Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, is featured in a recent ...

LGVN - Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B(TM) for the Treatment of Mild Alzheimer's

LOS ANGELES, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via IBN -- Longeveron Inc. (NASDAQ: LGVN) , a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions, today announces that it has been f...
LGVN - SPWR, OMER and MNTS among pre-market losers

2023-10-17 08:25:48 ET Losers: Evelo Biosciences ( EVLO ) -40% announces top-line results from its Phase 2 clinical study with EDP2939 in moderate psoriasis . Purple Biotech Ltd ( PPBT ) -21% announces $5 Million registered direct offering. Netscout Systems...

LGVN - InvestorNewsBreaks - Longeveron Inc. (NASDAQ: LGVN; LGVNR) Closes on $4M Registered Direct Offering

Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, closed on its previously...

LGVN - Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MIAMI, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (...
Previous 10 Next 10